A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Efficacy of LQ036 Single-Domain Antibody Nebulization Solution in Patients With Poorly Controlled Asthma
Latest Information Update: 27 Jun 2026
At a glance
- Drugs LQ 036 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Shanghai Novamab Biopharmaceuticals
Most Recent Events
- 11 Apr 2025 New trial record